NL-OMON34342招募中不适用
Donor leukapheresis for T-cell receptor gene therapy for treatment of metastatic melanoma (skin cancer) - Donor leukapheresis for T-cell receptor gene therapy
ederlands Kanker Instituut0 个研究点目标入组 2 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 2
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patient with a stage IV melanoma
- •Minimum age 18
- •ECOG performance status max. 1
- •HLA-A@-positive patients
- •negative for hepatitis A, B, C and HIV
- •Thrombocytes at least 100*109/L
- •Erythrocytes at least ... *109/L
- •Hemoglobin at least 5 mmol/L
- •Leukocytes at least ... *109/L
- •ALAT/ASAT less than three times the upper limit of normal
- •creatinin clearance 50ml/min or more
- •total bilirubin at least 20 um/L
- •life expectancy at least three months
- •patients using anticoagulans cannot attend in this study
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Administration of leukemia-reactive donor T cells after allogeneic stem cell transplantation or donor lymphocyte infusion to patients with persistent or relapsed mature B cell neoplasm with blood and/or bone marrow involvementpersistent or relapsed mature B cell neoplasm with blood and/or bone marrow involvementEUCTR2012-003691-40-NLeiden University Medical Center
已完成
2 期
Administration of leukemia-reactive donor T cells after allogeneic stem cell transplantation or donor lymphocyte infusion to patients with persistent or relapsed mature B cell neoplasm with blood and/or bone marrow involvementleukemialymfomen10024324lymphomaNL-OMON37016eids Universitair Medisch Centrum4
招募中
不适用
Adoptive therapy with TCR gene-engineered T cells to treat patients with MAGE-C2-positive melanoma and head and neck cancer.head and neck squamous cell carcinomamaligne melanomauveal melanoma100300541002765610040900skin cancerNL-OMON52657Erasmus MC, Universitair Medisch Centrum Rotterdam20
招募中
2 期
MAGE-C2 TCR T cell therapy2024-516922-70-00Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)20
尚未招募
不适用
Adoptive Transfer of T cell Receptor-engineered T cells to treat hepAtocellular Carcinoma recurrence after liver Transplantation: a preclinical feasibility studyLiver CancerPrimary Liver Cell Carcinoma100196541000381610019815NL-OMON47991Erasmus MC, Universitair Medisch Centrum Rotterdam35